Latest Updates

PepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments

– Niels Svenstrup, Ph.D., will serve as Senior Vice President of Chemistry, Manufacturing & Controls – David Pelissier, CPA, will serve as Vice President of Finance – New leaders will support PepGen in establishing its U.S. presence, building its financial strategy and advancing its pipeline BOSTON and…

PepGen to Present at Stifel’s 3rd Annual CNS Day

Boston, Mass. and Oxford, UK (March 23, 2021) – PepGen, Inc. a biotechnology company developing transformative therapies for individuals living with neuromuscular and neurologic diseases, today announced that Dr. James McArthur, CEO, will present at Stifel’s 3rd Annual CNS Day virtual conference. The presentation is scheduled for Wednesday, March 31,…

PepGen to Present Late-Breaking Data from Novel Enhanced Delivery Oligonucleotide (EDO) Pipeline at 2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference

EDO platform demonstrates potentially best-in-class safety and efficacy profile in addressing DMD and DM1 disease phenotypes; advancing rapidly to the clinic with first-in-human studies expected to initiate in early 2022 Boston, Mass. and Oxford, UK (March 15, 2021) – PepGen, an emerging biotechnology company focused on developing transformative therapies for…

PepGen Announces Formation of Scientific Advisory Board

World-renowned Neuromuscular Disease and Oligonucleotide experts Matthew Wood, M.D., Ph.D., Art Krieg, M.D., Elizabeth McNally, M.D., Ph.D., Charles Thornton, M.D., Jonathon Watts, Ph.D., and Brenda Wong, M.D., to join PepGen’s Scientific Advisory Board Boston, Mass. and Oxford, UK (February 26, 2021) – PepGen, an emerging biotechnology company focused on transforming…

PepGen Announces Appointment of James McArthur, Ph.D., as President and Chief Executive Officer

Seasoned biotech executive with deep experience and proven track record in successfully leading rare disease companies through rapid growth and development   Boston, Mass. and Oxford, UK (February 4th, 2021) – PepGen, a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the enhanced…

PepGen raises $45M Series A

RA Capital Management leads $45M Series A financing for PepGen’s next-generation oligonucleotide platform targeting Duchenne muscular dystrophy and other rare neuromuscular and cardiac diseases. PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also…

PepGen joins forces with researchers to tackle brain comorbidity in DMD

We are excited to announce that PepGen will be part of an international project focusing on the role of the brain in Duchenne and Becker muscular dystrophy. Further details on this project can be found in the press release below:   The BIND project is the first project of…

Recent publication honoured by the OTS

A recent publication utilising the precursor technology that underpins PepGen’s platform has been awarded ‘Paper of the Month‘ by the Board of Directors and the Scientific Advisory Council of the Oligonucleotide Therapeutics Society (OTS). In addition, this publication is currently under consideration for the OTS Paper of the…

PepGen attends BioTrinity in London

PepGen attended the BioTrinity conference from the 29th of April to the 1st of May 2019. The company was represented by Damian Marron (Chairman of the Board), Dr Caroline Godfrey (CEO) and Dr Sonia Bracegirdle (CBO) at this event. Alongside meetings with potential investors and partners,…